The hormone-sensitive LNCaP prostate cancer cell lines, that show appreciable levels of USP7 (Figure 1A), were treated with various concentrations of the USP7 inhibitor P5091 or vehicle, with or without DHT stimulation. The gene discussed is USP7; the disease is prostate carcinoma.